$SGMO
Sangamo Therapeutics Inc

2015 Q3 Form 10-Q Financial Statement

#000156459015009009 Filed on October 30, 2015

View on sec.gov

Income Statement

Concept 2015 Q3 2014 Q4 2014 Q3
Revenue $8.569M $14.95M $12.42M
YoY Change -30.99% 117.67% 117.57%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.560M $4.330M $3.730M
YoY Change 22.25% 5.35% 18.04%
% of Gross Profit
Research & Development $16.69M $14.99M $16.29M
YoY Change 2.46% 39.05% 87.18%
% of Gross Profit
Depreciation & Amortization $300.0K $100.0K $100.0K
YoY Change 200.0% -50.0% 0.0%
% of Gross Profit
Operating Expenses $21.25M $19.42M $20.07M
YoY Change 5.89% 29.1% 69.15%
Operating Profit -$12.69M
YoY Change
Interest Expense $100.0K $150.0K $110.0K
YoY Change -9.09% 400.0% 1000.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$12.58M -$4.320M -$7.545M
YoY Change 66.79% -46.93% 22.68%
Income Tax -$3.339M $0.00
% Of Pretax Income
Net Earnings -$9.245M -$4.319M -$7.545M
YoY Change 22.53% -46.97% 22.78%
Net Earnings / Revenue -107.89% -28.89% -60.76%
Basic Earnings Per Share
Diluted Earnings Per Share -$132.4K -$62.96K -$110.7K
COMMON SHARES
Basic Shares Outstanding 68.40M 68.16M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q3 2014 Q4 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $219.3M $226.2M $162.4M
YoY Change 35.05% 63.44% 35.11%
Cash & Equivalents $34.29M $6.030M $11.21M
Short-Term Investments $185.0M $220.2M $151.2M
Other Short-Term Assets $1.000M $183.0K $887.0K
YoY Change 12.74% -4.19% 495.3%
Inventory
Prepaid Expenses $623.0K $751.0K
Receivables $7.000M $10.37M $8.474M
Other Receivables $400.0K $400.0K $300.0K
Total Short-Term Assets $227.7M $190.9M $173.2M
YoY Change 31.48% 96.23% 37.28%
LONG-TERM ASSETS
Property, Plant & Equipment $3.063M $1.479M $1.566M
YoY Change 95.59% 5.19% 4.82%
Goodwill $1.585M $1.585M $1.585M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments $0.00 $47.30M $69.00M
YoY Change -100.0% 22.22% 443.31%
Other Assets $185.0K $139.0K $108.0K
YoY Change 71.3% 247.5%
Total Long-Term Assets $4.833M $52.33M $74.18M
YoY Change -93.48% 20.13% 421.54%
TOTAL ASSETS
Total Short-Term Assets $227.7M $190.9M $173.2M
Total Long-Term Assets $4.833M $52.33M $74.18M
Total Assets $232.5M $243.2M $247.3M
YoY Change -6.0% 72.69% 76.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.900M $5.525M $8.000M
YoY Change 11.25% 82.83% 196.3%
Accrued Expenses $2.800M $3.400M $2.700M
YoY Change 3.7% -8.11% 35.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $22.10M $20.88M $19.49M
YoY Change 13.37% 106.12% 178.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $6.800M $14.90M $17.00M
YoY Change -60.0% 81.71% 136.11%
Total Long-Term Liabilities $6.800M $14.90M $17.00M
YoY Change -60.0% 81.71% 136.11%
TOTAL LIABILITIES
Total Short-Term Liabilities $22.10M $20.88M $19.49M
Total Long-Term Liabilities $6.800M $14.90M $17.00M
Total Liabilities $29.00M $36.58M $37.21M
YoY Change -22.06% 91.23% 161.57%
SHAREHOLDERS EQUITY
Retained Earnings -$328.6M -$324.2M
YoY Change 8.74% 10.29%
Common Stock $535.2M $534.3M
YoY Change 26.28% 86922.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $203.6M $206.6M $210.1M
YoY Change
Total Liabilities & Shareholders Equity $232.5M $243.2M $247.3M
YoY Change -6.0% 72.69% 76.22%

Cashflow Statement

Concept 2015 Q3 2014 Q4 2014 Q3
OPERATING ACTIVITIES
Net Income -$9.245M -$4.319M -$7.545M
YoY Change 22.53% -46.97% 22.78%
Depreciation, Depletion And Amortization $300.0K $100.0K $100.0K
YoY Change 200.0% -50.0% 0.0%
Cash From Operating Activities -$14.20M -$2.700M -$5.800M
YoY Change 144.83% 58.82% 28.89%
INVESTING ACTIVITIES
Capital Expenditures -$200.0K $0.00 -$100.0K
YoY Change 100.0% 0.0%
Acquisitions
YoY Change
Other Investing Activities $22.20M -$200.0K -$83.40M
YoY Change -126.62% -99.71% -6515.38%
Cash From Investing Activities $21.90M -$400.0K -$83.40M
YoY Change -126.26% -99.42% -6515.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 15.80M -2.100M 1.200M
YoY Change 1216.67% -520.0% -98.32%
NET CHANGE
Cash From Operating Activities -14.20M -2.700M -5.800M
Cash From Investing Activities 21.90M -400.0K -83.40M
Cash From Financing Activities 15.80M -2.100M 1.200M
Net Change In Cash 23.50M -5.200M -88.00M
YoY Change -126.7% -92.58% -228.84%
FREE CASH FLOW
Cash From Operating Activities -$14.20M -$2.700M -$5.800M
Capital Expenditures -$200.0K $0.00 -$100.0K
Free Cash Flow -$14.00M -$2.700M -$5.700M
YoY Change 145.61% 58.82% 29.55%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3063000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1479000
CY2015Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
185000
CY2014Q4 us-gaap Other Assets Current
OtherAssetsCurrent
183000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
190879000
CY2015Q3 us-gaap Assets Current
AssetsCurrent
227683000
CY2015Q3 us-gaap Goodwill
Goodwill
1585000
CY2014Q4 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
47260000
CY2014Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1870000
CY2015Q3 us-gaap Assets
Assets
232516000
CY2015Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
8888000
CY2015Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2779000
CY2014Q4 sgmo Escrow Liability
EscrowLiability
275000
CY2014Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
1800000
CY2014Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
748000
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
69892000
CY2015Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
57000
CY2015Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9188000
CY2015Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
101000
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
21254000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12685000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-30777000
us-gaap Revenues
Revenues
30918000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22098000
us-gaap Net Income Loss
NetIncomeLoss
-26690000
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
534518000
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
130000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-4908000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-24616000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
168627000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
203175000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
745000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
400000
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
1870000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-681000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-843000
us-gaap Share Based Compensation
ShareBasedCompensation
8664000
us-gaap Share Based Compensation
ShareBasedCompensation
6165000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-1800000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-4087000
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-24000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3364000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-129000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2534000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-74000
CY2015Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12584000
CY2014Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7545000
CY2015Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3339000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-4087000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
14861000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2963000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
176385000
CY2014Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
20000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
68230000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
69622000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
79000
CY2014Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7525000
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-25000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5319000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1059000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3619000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-530000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
76605000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
559000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-100339000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10525000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
20652000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
104321000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
28257000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1019000
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11205000
CY2014Q1 sgmo Number Of Research Program
NumberOfResearchProgram
2
CY2015Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
12747000
CY2015Q3 us-gaap Marketable Securities
MarketableSecurities
185042000
CY2015Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
197789000
CY2014Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1800000
CY2014Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1800000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
-1800000
CY2015Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0
CY2015Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
197735000
CY2014Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
223399000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2327000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
32221000
sgmo Net Proceeds From Issuance Public Offering
NetProceedsFromIssuancePublicOffering
93796000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
48000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6248000
sgmo Proceeds From Claims Settlement
ProceedsFromClaimsSettlement
14452000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10186000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value measurements, business combinations including the fair value of the contingent consideration liability for payments to former Ceregene, Inc. (Ceregene) stockholders and intangible assets related to the acquisition of Ceregene, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. </p></div>
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
33000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
58000
CY2015Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
197789000
CY2014Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
223374000
us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0
CY2014 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0
us-gaap Income Tax Expense Benefit Intraperiod Tax Allocation
IncomeTaxExpenseBenefitIntraperiodTaxAllocation
-3400000
CY2015Q3 us-gaap Income Tax Expense Benefit Intraperiod Tax Allocation
IncomeTaxExpenseBenefitIntraperiodTaxAllocation
-3400000
CY2015Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2828000
CY2014Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2129000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8664000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6165000
sgmo Settlement Recognized As Additional Paid In Capital Net Of Tax
SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax
8700000

Files In Submission

Name View Source Status
0001564590-15-009009-index-headers.html Edgar Link pending
0001564590-15-009009-index.html Edgar Link pending
0001564590-15-009009.txt Edgar Link pending
0001564590-15-009009-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sgmo-10q_20150930.htm Edgar Link pending
sgmo-20150930.xml Edgar Link completed
sgmo-20150930.xsd Edgar Link pending
sgmo-20150930_cal.xml Edgar Link unprocessable
sgmo-20150930_def.xml Edgar Link unprocessable
sgmo-20150930_lab.xml Edgar Link unprocessable
sgmo-20150930_pre.xml Edgar Link unprocessable
sgmo-ex101_99.htm Edgar Link pending
sgmo-ex311_6.htm Edgar Link pending
sgmo-ex312_9.htm Edgar Link pending
sgmo-ex321_10.htm Edgar Link pending
Show.js Edgar Link pending